The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression
出版年份 2021 全文链接
标题
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression
作者
关键词
Alzheimer's disease, Depression, Comorbidity, Multi-target-directed ligands
出版物
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 229, Issue -, Pages 114045
出版商
Elsevier BV
发表日期
2021-12-08
DOI
10.1016/j.ejmech.2021.114045
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The Impact of Disease Comorbidities in Alzheimer's Disease
- (2021) Jose A. Santiago et al. Frontiers in Aging Neuroscience
- Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer’s Disease
- (2021) Michele Rossi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Depression in Dementia or Dementia in Depression? Systematic Review of Studies and Hypotheses
- (2020) Agnieszka Brzezińska et al. Current Alzheimer Research
- The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer’s Disease: A Preclinical Study in APP/PS1 Transgenic Mice
- (2020) Hao Wang et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
- (2019) Justin M. Long et al. CELL
- Donepezil Treatment in Patients With Depression and Cognitive Impairment on Stable Antidepressant Treatment: A Randomized Controlled Trial
- (2018) Davangere P. Devanand et al. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
- Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer’s Disease Agents
- (2018) Yixiang Xu et al. ACS Chemical Neuroscience
- Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
- (2018) Qi Li et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel Terminal Bipheny-Based Diapophytoene Desaturases (CrtN) Inhibitors as Anti-MRSA/VISR/LRSA Agents with Reduced hERG Activity
- (2017) Baoli Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo
- (2017) Shuaishuai Ni et al. JOURNAL OF MEDICINAL CHEMISTRY
- Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study
- (2017) Jorge Browne et al. BMJ Open
- The role of 5-HT receptors in depression
- (2017) Christine N. Yohn et al. Molecular Brain
- Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases
- (2016) Cornelis J. Van der Schyf DRUG DEVELOPMENT RESEARCH
- Multi-target therapeutics for neuropsychiatric and neurodegenerative disorders
- (2016) Priya Bawa et al. DRUG DISCOVERY TODAY
- The 5-HT1A receptor in Major Depressive Disorder
- (2016) Joshua Kaufman et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- The prevalence of neuropsychiatric symptoms in Alzheimer's disease: Systematic review and meta-analysis
- (2016) Qing-Fei Zhao et al. JOURNAL OF AFFECTIVE DISORDERS
- Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents
- (2016) Xiaokang Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Alzheimer´s Disease associated with Psychiatric Comorbidities
- (2015) Michelle L. Garcez et al. ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS
- The Prevalence of Depression in Alzheimer’s Disease: A Systematic Review and Meta-Analysis
- (2015) Song Chi et al. Current Alzheimer Research
- Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT4R) Agonist Activities As Potential Agents against Alzheimer’s Disease: The Design of Donecopride
- (2015) Christophe Rochais et al. JOURNAL OF MEDICINAL CHEMISTRY
- Depression associated with dementia
- (2015) H. Gutzmann et al. ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE
- Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia
- (2015) Donovan T. Maust et al. JAMA Psychiatry
- Behavioral and Psychological Symptoms in Alzheimer’s Disease
- (2014) Xiao-Ling Li et al. Biomed Research International
- The Epidemiological Modelling of Major Depressive Disorder: Application for the Global Burden of Disease Study 2010
- (2013) Alize J. Ferrari et al. PLoS One
- Behavioral and Psychological Symptoms of Dementia
- (2012) J. Cerejeira et al. Frontiers in Neurology
- Depression and risk of developing dementia
- (2011) Amy L. Byers et al. Nature Reviews Neurology
- 5-HT1A receptor-regulated signal transduction pathways in brain
- (2010) Abigail M. Polter et al. CELLULAR SIGNALLING
- Development of an Efficient Therapeutic Agent for Alzheimer's Disease: Design and Synthesis of Dual Inhibitors of Acetylcholinesterase and Serotonin Transporter
- (2010) Narihiro Toda et al. CHEMICAL & PHARMACEUTICAL BULLETIN
- The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies
- (2010) Inge Klinkenberg et al. NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Alzheimer's Disease
- (2010) Henry W. Querfurth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vilazodone: A 5-HT1AReceptor Agonist/Serotonin Transporter Inhibitor for the Treatment of Affective Disorders
- (2009) Lee A. Dawson et al. CNS Neuroscience & Therapeutics
- Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
- (2009) Arif Khan EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 5-HT1A receptor function in major depressive disorder
- (2009) Jonathan Savitz et al. PROGRESS IN NEUROBIOLOGY
- Serotonin Receptors
- (2008) David E. Nichols et al. CHEMICAL REVIEWS
- Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
- (2008) Andrea Cavalli et al. JOURNAL OF MEDICINAL CHEMISTRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now